INVESTER I SCANCELL HOLDINGS MED ENDAVU: Køb Scancell Holdings ($SCLP) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Scancell Holdings, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.

Scancell Holdings plc is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer. Its current research and development activities use four technology platforms: Moditope and ImmunoBody, which support therapeutic vaccine development, and GlyMab and AvidiMab, which are designed to generate and enhance antibody-based treatments. The company’s pipeline includes Modi-1, an active peptide immunotherapy being evaluated across several solid tumors, including renal, head and neck, ovarian, and triple-negative breast cancers. It also develops SCIB1 and iSCIB1+, immunotherapies targeting melanoma, alongside SC134, an antibody program for small-cell lung cancer. Through its work on tumor-specific glycans, immune activation, and receptor clustering, Scancell Holdings plc operates at the intersection of biotechnology, oncology, and translational medicine, addressing areas where existing cancer treatments may not provide sufficient clinical benefit. Headquartered in Oxford, United Kingdom, the company’s role in the financial market reflects the characteristics of a research-driven biotechnology enterprise whose business is centered on advancing proprietary therapeutic candidates through clinical development.